MTEC Educational Webinar

webinar

Commercializing Medical Devices – From Technology to Product

1-2 pm EST

Commercializing Medical Devices – From Technology to Product

Date & Time

October 21, 2026

Description

MTEC hosted Luke Palombo, Director of R&D, and Justin Inslee, Director of Engineering, of Tensentric for “Commercializing Medical Devices: From Technology to Product.” Tensentric is an ISO 13485-certified product realization company with FDA-registered manufacturing and more than 500 projects over 17 years. The presenters framed the central challenge for MTEC’s dual-use developers: a government contract may have one key stakeholder and a written requirements list, but a commercial device answers to many stakeholders whose needs must be teased out and balanced. Meeting the contract is not the same as building a product the market will buy. A commercially viable device must be manufacturable, usable, testable, clearable, reliable, serviceable and, ultimately, desirable at a price the market will pay. Citing a 2010 Stanford Biodesign survey of roughly 200 device companies, Luke noted that even 510(k) products requiring a clinical trial spend about four years, and most of their development cost, after the IDE process begins, so early efficiency pays off.

The core of the session was Tensentric’s “Phase Zero” philosophy: mature the product architecture before entering formal design controls, while design alternatives are many and the cost of change is low. Its tools include Project Essentials, which captures the rationale behind each requirement; prototyping at the lowest fidelity that still earns useful feedback; and AgileRx, which runs two-week sprints inside a phase-gated, compliant process. Two case studies made the point concrete. Luke described an early-career rapid DNA analysis platform whose product vision was defined only by its contract; it met every requirement and reached manufacturing, but orders never followed. Justin contrasted it with a Tensentric point-of-care molecular diagnostic whose first three milestones were all Phase Zero work, de-risking subsystem interfaces, form factor and consumable cost before formal verification began. Both urged teams to engage FDA early through a Q-Submission.

In the Q&A, the presenters, speaking as developers rather than regulatory experts, said FDA’s new Quality Management System Regulation (QMSR), in effect since February 2, 2026, does not change how they run Phase Zero: it harmonizes with ISO 13485, and early exploratory work generally sits outside the formal Design Development File until a concept is selected for detailed design. Asked what successful clients have in common, they pointed to balance (enough knowledge of the endpoint to plan for it without being paralyzed by it), a real problem with engaged stakeholders, a bounded minimum viable product, and a clear decision-maker. As Justin put it, “The only thing worse than the wrong decision is to make no decision at all.” Tensentric’s manufacturing is built for market entry, with a path to high-volume contract manufacturers such as Jabil and Plexus as a product scales.

The presentation slides and full recording are available at the links below, and Luke and Justin welcome follow-up conversations (luke.palombo@tensentric.com, justin.inslee@tensentric.com).

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.

Commercializing Medical Devices – From Technology to Product | MTEC